7 Best Peptides for Addiction

What to Know Before Choosing a Peptide for Addiction

The peptide landscape for addiction is messier and more interesting than almost any other health goal in this library. A handful of compounds have actual human clinical trial data, which is uncommon for peptides in general. A larger group circulates in recovery communities and biohacking forums for their effects on anxiety, sleep, neurological repair, and mood, without any addiction-specific trial data behind those uses. Both groups belong in this guide, because the inclusion criterion is straightforward: a peptide earns a slot if people use it for this goal, or are actively discussing using it. FDA approval is not the filter. Evidence depth is not the filter. What matters is whether the compound is genuinely part of the conversation around addiction recovery, and for each one the evidence is described honestly rather than used as a reason to leave it off the list.

One foundational fact shapes the whole article: no peptide is FDA-approved for addiction treatment specifically. The GLP-1 receptor agonists in the first half of this list are approved drugs for diabetes and obesity that are now being studied off-label for substance use disorders. For alcohol and opioid use disorders, the standard of care remains non-peptide medications like naltrexone, buprenorphine, and acamprosate. The peptides here are emerging options, some with real clinical momentum and some with only community-level support, and that distinction matters both for how you read the evidence and for how you would access any of them.

The entries below are numbered and ordered by how prominently each compound appears in published research and documented real-world use. A higher number is not a mark against a compound, and a lower number is not a recommendation. The numbers are a spine for the list, not a verdict on which peptide belongs in anyone's protocol.

1. Semaglutide: For Alcohol and Opioid Craving Reduction

Semaglutide is the most clinically advanced peptide in the addiction space right now, and the only compound in this list with published human trial results specifically for a substance use disorder. It is a GLP-1 receptor agonist, meaning it mimics glucagon-like peptide-1, a hormone the gut releases after eating that signals fullness and satisfaction to the brain. That satiety signal turns out to share circuitry with the brain's reward system, and that overlap is the mechanistic story behind why GLP-1 drugs are generating serious attention in addiction research.

GLP-1 receptors are located in the ventral tegmental area and the nucleus accumbens, two regions at the heart of the mesolimbic dopamine pathway. Think of this pathway as the brain's motivational engine: drugs of abuse hijack it to produce the craving and compulsive seeking that define addiction. When semaglutide binds to GLP-1 receptors in these areas, it blunts the dopamine surge that substances trigger, effectively turning down the volume on the reward signal. In animal models this mechanism reduced cocaine-seeking and alcohol consumption consistently. The human data is starting to follow.

In a published trial examining alcohol use disorder, semaglutide reduced both alcohol craving and alcohol intake. A separate trial registered as NCT06548490 is currently evaluating semaglutide for reducing illicit opioid use in outpatient adults, and a collaboration with Yale researchers is investigating it for cocaine addiction. A large 2025 study published in the BMJ examined people with pre-existing substance use disorders who were prescribed GLP-1 agonists and found the drug class was associated with reduced risk of several adverse outcomes across substance categories. The evidence is still accumulating, but semaglutide has more peer-reviewed human data for addiction than any other compound in this article.

The regulatory context is worth being clear about. Semaglutide is FDA-approved for type 2 diabetes and obesity, not for addiction. Any use for alcohol, opioid, or stimulant disorders is currently off-label. Access runs through a physician who can prescribe it for an approved indication. Unapproved compounded versions lack the FDA quality review that comes with an approved formulation, which is a real consideration given the safety stakes in a recovery context.

2. Liraglutide: For Opioid Craving and Drug Reward Reduction

Liraglutide is another GLP-1 receptor agonist and the compound with the most established human research on drug reward reduction outside of semaglutide. Like semaglutide, it acts on GLP-1 receptors in the brain's reward circuitry to suppress the dopamine-mediated reinforcement that substances produce. In rodent and primate models, liraglutide consistently reduced chronic drug intake across multiple substance categories. The human research is now advancing beyond those models.

A randomized, double-blinded clinical trial is currently investigating liraglutide for opioid craving reduction. This is a meaningful development: a well-designed, placebo-controlled trial targeting one of the hardest clinical problems in addiction medicine. Results are pending, but the existence of the trial reflects that the research community views liraglutide as a serious candidate. That is a different status from a compound being speculated about in community forums.

Liraglutide has been FDA-approved for type 2 diabetes and obesity since 2010 and 2014 respectively, so its safety profile in humans is among the most thoroughly characterized of any peptide in this list. The addiction application remains off-label, but the pharmacology operates through the same well-understood mechanism. Side effects, primarily gastrointestinal, including nausea, vomiting, and appetite suppression, are well-characterized from the approved indications and are directly relevant for anyone considering liraglutide in a recovery setting.

3. Exenatide: For Nicotine Cessation and Alcohol Use Support

Exenatide is the GLP-1 receptor agonist with the longest human clinical history in addiction research, though its results are more mixed than those of its counterparts. It was the first GLP-1 drug to appear in a published human trial for addiction: a pilot study pairing exenatide with nicotine replacement therapy found the combination improved smoking abstinence and reduced cravings relative to nicotine replacement alone. That makes exenatide the only compound in this list with a published human result specifically for tobacco use disorder. Three trials on ClinicalTrials.gov are currently investigating GLP-1 agonists for tobacco use, reflecting the interest that pilot result generated.

The alcohol story is more complicated. A double-blind, randomized, placebo-controlled crossover study examined the acute effects of exenatide on alcohol intake in heavy drinkers. The results have been described as limited and mixed, with no significant overall effect on alcohol use disorder, though a subgroup of obese participants showed reduced intake. A separate study of low-dose exenatide on cocaine self-administration in humans found no effect. The animal data for exenatide across multiple substances is considerably more positive than the human results, which is a common pattern in addiction pharmacology and a reason to read the preclinical evidence with appropriate skepticism while larger trials complete.

Exenatide is FDA-approved for type 2 diabetes. Any use for nicotine, alcohol, or stimulant disorders is off-label. For nicotine specifically, it has more published human support than any other compound in this article. For alcohol and cocaine, the human evidence is incomplete and the preclinical-to-human translation has not been as straightforward.

4. BPC-157: For Neurological Recovery and Tissue Repair After Substance Use

BPC-157 reaches this list by a very different route than the GLP-1 agents above. It has no published randomized controlled trial for addiction in humans. A 2026 review confirmed it remains investigational with an unknown safety profile, and the FDA classifies it as a research chemical rather than a dietary supplement. The reason it belongs here is the inclusion criterion: people are actively using and discussing BPC-157 for addiction recovery, particularly for neurological repair after stimulant use, and that use is widespread enough across community forums that omitting it would make this article less honest, not more.

BPC-157 is a synthetic peptide derived from a protein found in gastric juice. Its strongest evidence base, drawn from animal studies, covers gut healing, angiogenesis (the growth of new blood vessels to damaged tissue), and reduction of inflammation in the central nervous system. Community users apply these properties to addiction recovery through a reasonable chain of reasoning: chronic substance use damages the gut lining and disrupts dopamine pathways in the brain, and BPC-157's repair-oriented profile may help restore some of that function. People recovering from amphetamine use in particular report improved mental clarity and focus. At least one forum user also reported anhedonia, a blunted ability to feel pleasure, after prolonged use, which is worth noting as a potential adverse effect.

The honest framing here is that the tissue repair evidence for BPC-157 is real and preclinically strong. The addiction-specific mechanism is theoretical rather than studied. The claim that it stabilizes dopamine pathways damaged by substance abuse is extrapolation, not a finding from addiction-model research. Anyone using BPC-157 for recovery support is working from a plausible hypothesis with no clinical confirmation, and they should know that. The gray market channel through which most people access it carries genuine quality and contamination risks that compound the uncertainty.

5. Selank: For Anxiety and Mood Stabilization in Early Recovery

Selank is a synthetic heptapeptide developed in Russia and used clinically there for anxiety and cognitive support for decades, though it carries no approved indication in the United States. It appears in addiction recovery discussions for a specific reason: the psychological dimension of early recovery, the anxiety, the stress sensitivity, the mood instability, is frequently what drives relapse, and Selank addresses that dimension more directly than the dopamine-focused mechanisms of the GLP-1 agents.

Its mechanism involves modulation of neuropeptides in the brain, with reported effects on the enkephalin system, which governs pain and emotional regulation, and on GABA-related pathways that control anxiety and stress responses. Users in recovery contexts report that Selank reduces baseline anxiety and emotional reactivity during the period when psychological cravings are highest. No randomized controlled trial for addiction exists as of 2026. The evidence base is a combination of clinical use data from Russia for anxiety and stress disorders, which is real but not well-represented in English-language peer-reviewed literature, and user-reported experience from community protocols applied to recovery settings.

Selank is often paired with Semax in community discussions, with Selank handling the anxiety and mood component and Semax handling cognitive recovery. It is available as a research chemical and is not FDA-approved for any indication in the United States. The safety profile based on its decades of use in Russia appears relatively benign, but the absence of rigorous Western clinical trial data means the full safety picture is not established. For someone navigating significant anxiety in early recovery, Selank is worth knowing about. The evidence base for this specific use is experiential rather than clinical.

6. Semax: For Cognitive Recovery and Focus Restoration

Semax is a synthetic analog of ACTH, the adrenocorticotropic hormone, developed in Russia and used there for neurological rehabilitation and cognitive support. In addiction recovery communities, it is used primarily for the cognitive symptoms that persist after substance use: the brain fog, difficulty concentrating, and dulled motivation that many people experience in the months after stopping. This phase of recovery does not have a dedicated pharmacological treatment in conventional medicine, which creates space for community experimentation with compounds like Semax.

The proposed mechanism most relevant to recovery involves Semax's effects on brain-derived neurotrophic factor, often abbreviated BDNF, which acts as a growth and maintenance signal for neurons, supporting their survival and the formation of new connections. Chronic substance use suppresses BDNF in the prefrontal cortex and reward-related brain regions. Restoring neurotrophic support in these areas is one way researchers think about supporting cognitive recovery. Semax also appears to modulate dopamine and serotonin signaling in ways that may support mood and motivation. No clinical trial for addiction exists as of 2026. Community users describe it as quite safe with positive results for focus and mental clarity, though individual accounts vary.

Semax is typically administered as a nasal spray, which sets it apart from the injectable peptides in this list and makes it more accessible to people who prefer non-injectable routes. It is not FDA-approved for any indication in the United States and is used clinically in Russia for neurological conditions under physician oversight. The evidence base for its use in addiction recovery is entirely user-reported, drawn from people applying it to a specific problem without formal study of that application.

7. Spexin: For Alcohol-Specific Craving Through a Novel Pathway

Spexin is the least-known compound in this list and arguably the one with the most scientifically interesting mechanism. It is a neuropeptide identified through genetic screening that acts on a pathway distinct from the GLP-1 axis and from the standard neurobiological targets of existing addiction medications. Research out of Columbia University, now at the technology transfer stage, has validated spexin's ability to reduce alcohol consumption in mouse models by inhibiting the urge to consume alcohol through this distinct pathway.

What makes spexin worth including rather than setting aside as just another preclinical compound is the specificity of the mechanistic finding and the institutional backing. The Columbia group identified spexin's connection to both obesity and alcohol use disorder pathways, placing it in interesting territory alongside the GLP-1 agents that also sit at the intersection of metabolic and reward circuitry. No human clinical trial data exists for spexin in addiction as of 2026. The current stage is preclinical, with the technology licensed for further development.

Spexin is not commercially available and is not accessible through a research chemical supplier in the way that BPC-157 or Semax might be. It belongs in this article because it represents a genuinely novel direction in addiction-specific peptide pharmacology, and because readers tracking the science of peptide-based addiction treatment should have it in their awareness. If you are looking for something available to use now, spexin is not a practical option. If you are following where the research is heading, it is one of the names worth watching.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved for addiction treatment?

No peptide is currently FDA-approved specifically for addiction treatment. Semaglutide, liraglutide, and exenatide are FDA-approved for diabetes and obesity, and any use for substance use disorders is off-label, meaning a physician can prescribe them for that purpose but the indication has not been formally reviewed or approved. BPC-157, Selank, Semax, and Spexin are not FDA-approved for any indication in the United States. The standard of care for alcohol and opioid use disorders remains non-peptide medications including naltrexone, buprenorphine, and acamprosate.

How do GLP-1 peptides reduce addiction-related cravings?

GLP-1 receptors are present in the brain regions that govern reward and motivation, particularly the ventral tegmental area and the nucleus accumbens. Drugs of abuse activate this circuitry to produce the dopamine surge that drives craving and compulsive behavior. When GLP-1 receptor agonists like semaglutide or liraglutide bind to these receptors, they blunt that dopamine release, reducing the rewarding signal that makes continued use so compelling. The satiety and reward pathways are more closely linked than most people realize, and that connection is what makes a class of metabolic drugs unexpectedly relevant to addiction medicine.

What is the difference between the GLP-1 peptides and the wellness peptides in this list?

The GLP-1 agents work directly on the neurobiological machinery of addiction, targeting the dopamine reward pathway with a mechanism that has been studied in humans and is generating real clinical trial data. The wellness peptides, BPC-157, Selank, and Semax, are used in recovery communities for adjacent purposes: repairing tissue and neurological damage, managing the anxiety and mood disruption of early recovery, and restoring cognitive function. None of them have addiction-specific human trial data. The practical access pathways are also very different: GLP-1 agents require a prescription, while the wellness compounds typically move through research chemical channels with all the quality and safety uncertainty that implies.

Is it safe to use these peptides for addiction recovery without a doctor?

Using any of these compounds without medical supervision carries real risks. For GLP-1 agents, self-administration outside a clinical framework means no monitoring for serious adverse effects, and unapproved compounded versions lack the quality controls of an FDA-reviewed formulation. For research-chemical peptides like BPC-157, Selank, and Semax, the absence of regulatory oversight means no guaranteed purity, accurate concentration, or sterility. Health Canada has issued explicit warnings against injecting peptides bought online, citing risks including contamination with heavy metals, bacteria, and inconsistent active ingredient content. Medical supervision is the appropriate framework for any of these compounds in a recovery context.

How long before these peptides show effects in a recovery context?

Timelines are not well-established for most of these compounds in addiction contexts, and the honest answer is that it varies considerably. The GLP-1 clinical trials have not published detailed timelines specifically for craving reduction. Community users of Selank and Semax in recovery settings report noticing anxiety and cognitive effects within days to a few weeks, but these are not controlled observations. How long any recovery support compound takes to show meaningful results depends on the substance involved, the duration and severity of prior use, and individual neurobiological factors that no general guide can predict accurately.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for addiction recovery in one place.